Mersana Therapeutics to Present at the Jefferies Global Healthcare Conference
May 31, 2018 16:01 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Strengthens Board of Directors Leadership with Appointment of Willard H. Dere, M.D., Professor at the University of Utah and Retired Chief Medical Officer of Amgen
March 19, 2018 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Appoints David A. Spellman as Chief Financial Officer
March 12, 2018 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics to Present at Upcoming Investor Conferences
February 07, 2018 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Outlines 2017 Milestones and 2018 Goals
January 08, 2018 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
December 20, 2017 16:01 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Added to NASDAQ Biotechnology Index
December 15, 2017 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Announces First Patient Dosed with XMT-1536 in Phase 1 Study in Patients with NaPi2b-Expressing Tumors
December 12, 2017 08:00 ET
|
Mersana Therapeutics, Inc.
Trial to Study Patients in Ovarian, NSCLC and Other Cancers XMT-1536 is Second Dolaflexin Antibody Drug Conjugate to Enter Clinical Trials CAMBRIDGE, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) --...
Mersana Announces Third Quarter 2017 Financial Results and Provides Business Updates
November 09, 2017 16:01 ET
|
Mersana Therapeutics, Inc.
Received FDA Clearance of IND Application for XMT-1536, a First-in-Class Dolaflexin® Antibody Drug Conjugate Targeting NaPi2b XMT-1522 Phase 1 Trial Continues Enrollment of Patients with Advanced...
Mersana Announces FDA Clearance of IND Application for XMT-1536, a First-in-Class Antibody Drug Conjugate Targeting NaPi2b
October 30, 2017 07:30 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...